BCR-ABL酪氨酸激酶抑制剂靶向治疗慢性粒细胞白血病（chronic myeloid leukemia, CML)能够达到良好的临床效应，然而随着其临床广泛应用，对其产生耐药逐渐增多。CML细胞多药耐药是目前导致化疗失败，缓解率降低，疾病复发的主要原因。本文就CML对BCR-ABL酪氨酸激酶靶向抑制剂耐药的主要机制进行了阐述。

Targeted therapy of chronic myeloid leukemia (CML) with BCR-ABL tyrosine

kinase inhibitor shows a very good clinical therapeutic effect, but the drug resistance

phenomena are increased with the wide use of tyrosine kinase inhibitor in clinic.

Multidrug resistance is the main reason of chemotherapy failure for CML patients

accompanied by the decrease in remission rate and the increase in relapse rate. This

review focus on the recent progress in the drug resistant mechanism for BCR-ABL tyrosine

kinase inhibitor

［1］O’Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with

interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid

leukemia［J］. New Engl J Med,2003,348(11): 994-1004.
［2］Gambacorti-Passerini CB, Gunby RH, Piazza R, et al.Molecular mechanisms of resistance

to imatinib in Philadelphia-chromosome-positive leukaemias［J］. Lancet Oncol,2003,4

(2):75-85.
［3］Mahon FX, Hayette S, Lagarde V,et al. Evidence that resistance to nilotinib may be

due to BCR-ABL, Pgp, or Src kinase overexpression［J］.Cancer Res,2008,68(23):9809-9816.
［4］Morinaga K, Yamauchi T, Kimura S, et al. Overcoming imatinib resistance using Src

inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly

established K562 variants with BCR-ABL gene amplification［J］. Int J Cancer,2008,122

(11):2621-2627.
 ［5］Gorre ME, Mohammed M, Ellwood K, et al.Clinical resistance to STI-571 cancer therapy

caused by BCR-ABL gene mutation of amplification［J］. Science, 2001, 293(5531):876-880.
［6］Hochhaus A, Kreil S, Corbin AS, et al.Molecular and chromosomal mechanisms of

resistance to imatinib (STI571) therapy［J］.Leukemia,2002,16(11):2190-2196.
［7］Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic

myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated

with a greater likelihood of progression to blast crisis and shorter survival: a study by

the GIMEMA Working Party on Chronic Myeloid Leukemia［J］. J Clin Oncol,2005,23(18): 4100

-4109.
［8］Kim SH, Kim D, Kim DW,et al. Analysis of Bcr-Abl kinase domain mutations in Korean

chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is

disease phase dependent［J］. Hematol Oncol, 2009, 27(4):190-197.
［9］O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia:

keeping resistance in check［J］. Expert Opin Investig Drugs, 2008,17(6): 865-878.
［10］Liu J, Joha S, Idziorek T, et al. BCR-ABL mutants spread resistance to non-mutated

cells through a paracrine mechanism［J］.Leukemia,2008,22(4):791-799.
［11］Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89

imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective

analysis from the French intergroup of CML (Fi (w)-LMC GROUP)［J］. Leukemia, 2006,20(6):

1061-1066.
［12］Goldman JM,Melo JV. BCR-ABL in chronic myelogenous leukemia-how does it work?［J］.

Acta Haematol, 2008,119(4):212-217.
［13］Preuner S, Denk D, Frommlet F, et al. Quantitative monitoring of cell clones

carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent

polymerase chain reaction (LD-PCR)［J］. Leukemia, 2008,22(10):1956-1961. 
［14］List AF, Kopecky KJ, Willman CL, et al. Cyclosporine inhibition of P-glycoprotein in

chronic myeloid leukemia blast phase［J］. Blood, 2002,100(5): 1910-1912.
［15］Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a

resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib

mesylate［J］. Leukemia,2004,18(3):401-408.
［16］Assef Y,Rubio F, Colo G,et al.Imatinib resistance in multidrug-resistant K562 human

leukemic cells［J］. Leukemia Res,2009,33(5):710-716.
［17］Zong Y, Zhou S, Sorrentino BP,et al.Reply to ‘Resistance reversal by RNAi silencing

of MDR1 in CML cells associated with increase in imatinib intracellular levels’ by Widmer

［J］. Leukemia, 2007,21(7):1562-1563.
［18］Crossman LC, Druker BJ,Deininger MN,et al. HOCT- 1 and resistance to imatinib［J］.

Blood,2005,106(3):1133-1134.
［19］Wang L, Giannoudis A, Lane S,et al. Expression of the uptake drug transporter hOCT1

is an important clinical determinant of the response to imatinib in chronic myeloid

leukemia［J］.Nature,2008,2(83):258-264.
［20］Thomas J, Wang L, Clark RE,et al.Active transport of imatinib into and out of

cells:implications for drug resistance［J］. Blood,2004,104(12):3739-3745.
［21］White DL,Saunders VA,Dang P,et al. Most CML patients who have a suboptimal response

to imatinib have impact of low OCT-1 activity low OCT-1 activity: higher doses of imatinib

may overcome the negative［J］. Blood, 2007, 110(12):4064-4072.
［22］Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for

BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia［J］. Nat

Genet,2004,36(5):453-461.
［23］Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors

in chronic myelogenous leukemia patients in complete cytogenetic remission following

imatinib mesylate treatment［J］. Blood,2003,101(12):4701-4707.
［24］Donato NJ, Wu JY, Stapley J,et al. BCR-ABL independence and LYN kinase

overexpression in chronic myelogenous leukemia cells selected for resistance to STI571［J

］. Blood,2003,101(2):690-698.
［25］Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyndependent form of

imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2［J］

. J Biol Chem,2004,79(33):34227-34239.
［26］Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase

overexpression in chronic myelogenous leukemia cells selected for resistance to STI571［J

］. Blood, 2003,101(2):690-698.
［27］Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosin phosphorylation

and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells［J］.

Blood, 2008,111(7):3821-3829.
［28］Park SJ, Kim MJ, Kim HB,et al. Sensitization of imatinib-resistant CML cells to

TRAIL-induced apoptosisis mediated through down-regulation of Bcr-Abl as well as c-FLIP［J

］. Biochem J,2009,420(1):73-81.
［29］Kuroda J,Puthalakath H,Cragg MS,et al. Bim and Bad mediate imatinib-induced killing

of Bcr-Abl-leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic［

J］. PNAS,2006,10(40):14907-14912.
［30］Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of

BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

［J］. Leukemia, 2006,20(10):1767-1773.
［31］Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with

BCR-ABL-positive leukemias treated with imatinib in a single center:a 4.5-year follow-up［

J］. Cancer,2005,103(8):1659-1669.
［32］Quintás-Cardama A, Cortes JE.Chronic myeloid leukemia: diagnosis and treatment［J］.

Mayo Clin Proc, 2006,81(7):973-988.
［33］Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier

progenitor population than imatinib in primary CML, but does not eliminate the quiescent

fraction［J］. Blood,2006,107(11): 4532-4539.
［34］Jiang X, Zhao Y,Smith C,et al.Chronic myeloid leukemia stem cells possess multiple

unique features of resistance to BCR-ABL targeted therapies［J］. Leukemia, 2007,21

(5):926-935.
［35］Ito K, Bernardi R, Morotti A,et al. PML targeting eradicates quiescent leukaemia-

initiating cells［J］.Nature,2008,453(7198):1072-1080.
［36］Arunasree KM, Roy KR, Anilkumar K,et al. Imatinib-resistant K562 cells are more

sensitive to celecoxib,a selective COX-2 inhibitor: Role of COX-2 and MDR-1［J］. Leuk

Rese,2008,2(32):855-864.
［37］Gambacorti-Passerini C, Barni R, le Coutre P,et al.Role of alpha1 acid glycoprotein

in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571［J

］. J Natl Cancer Inst,2000,10(20):1641-1651.
［38］Jorgensen HG,Elliott MA, Allan EK, et al. alpha 1-Acid glycoprotein expressed in the

plasma of chronic myeloid leukemia patients does not mediate significant in vitro

resistance to STI571［J］.Blood,2002,10(99):713-715.
［39］Guo Y, Zheng G,Jin X,et al. HA117 gene increased the multidrug resistance of K562

cells in vitro: an investigation to the function of a novel gene related to drug

resistance［J］.Clin Cancer Res,2009,1(63):63-69.
［40］Tipping AJ,Deininger MW,Goldman JM, et al. Comparative gene expression profile of

chronic myeloid leukemia cells innately resistant to imatinib mesylate［J］. Exp

Hematol,2003,8(31):1073-1080.
［41］Kominsky DJ, Klawitter J, Brown JL,et al. Abnormalities in glucose uptake and

metabolism in imatinib-resistant human BCR-ABL-positive cells［J］. Clin Cancer

Res,2009,15(10):3442-3450.
［42］Klawitter J, Kominsky DJ, Brown JL, et al. Metabolic characteristics of imatinib

resistance in chronic myeloid leukaemia cell［J］. Br J Pharmacol,2009,158(6):588-600.
［43］Pocaly M,Lagarde V,Etienne G. Overexpression of the heat-shock protein 70 is

associated to imatinib resistance in chronic myeloid leukemia［J］. Leukemia, 2007, 21

(1):93-101.